AVDL vs LLY โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AVDL Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Valuation, Momentum & Technical, Options & Structure while LLY counters with relative strength in Growth & Margin. Fundamentally, AVDL trades at 28.8x Forward P/E with 2.5% operating margin (+54.9% YoY revenue) versus LLY at 26.5x Forward P/E and 51.2% operating margin (+38.6% YoY). In options structure, AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against LLY sits in CONSOLIDATION (23rd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AVDL | LLY | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.1B | $1.20T | Larger Scale | LLY |
| Trailing P/E Ratio Valuation | 16.8x | 44.9x | Lower Multiple | AVDL |
| Forward P/E Ratio Valuation | 28.8x | 26.5x | Lower Multiple | LLY |
| Revenue Growth (YoY) Growth | +54.9% | +38.6% | Higher Growth | AVDL |
| Operating Margin (TTM) Profitability | 2.5% | 51.2% | Higher Margin | LLY |
| Net Profit Margin Profitability | -0.1% | 31.9% | Higher Margin | LLY |
| Return on Equity (ROE) Capital Efficiency | -0.3% | 86.0% | Higher ROE | LLY |
| 52-Week Range Position Momentum | 89% ($6โ$24) | 80% ($851โ$1,475) | Stronger Trend | AVDL |
| Beta / 30D Volatility Risk Regime | 0.14ฮฒ ยท 2% Vol | 0.32ฮฒ ยท 36% Vol | Lower Realized Risk | AVDL |
| Unified Institutional Score Composite Signal | 62.9 / 100 (BUY) | 41.4 / 100 (SELL) | Higher Composite | AVDL |